Paracrine-mediated osteoclastogenesis by the osteosarcoma MG63 cell line: Is RANKL/RANK signalling really important?

Clinical and Experimental Metastasis

Volumn 28, Issue 6, 2011, Pages 505-514

  Costa Rodrigues, J ^a   Teixeira, C A ^a,b   Fernandes, M H ^a  

^a Portugal   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Conditioned media; MG63 cell line; Osteoclast; Osteoclastogenesis

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; CALCIUM PHOSPHATE; COLONY STIMULATING FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE ACTIVATION; HUMAN; HUMAN CELL; ONCOGENE C MYC; ONCOGENE SRC; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOSARCOMA CELL; PARACRINE SIGNALING; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL;

ADULT; BASE SEQUENCE; CULTURE MEDIA, CONDITIONED; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; OSTEOCLASTS; OSTEOSARCOMA; PARACRINE COMMUNICATION; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 79960899602     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-011-9387-7     Document Type: Article

References (54)

1. DJ Hadjidakis II Androulakis 2006 Bone remodeling Ann NY Acad Sci 1092 385 396 17308163 10.1196/annals.1365.035 1:CAS:528:DC%2BD2sXjtlajt7w%3D (Pubitemid 47092355)
2. LG Raisz 2005 Pathogenesis of osteoporosis: concepts, conflicts, and prospects J Clin Invest 115 3318 3325 16322775 10.1172/JCI27071 1:CAS:528:DC%2BD2MXhtlSqtLzJ (Pubitemid 43121814)
3. M Zaidi 2007 Skeletal remodeling in health and disease Nat Med 13 791 801 17618270 10.1038/nm1593 1:CAS:528:DC%2BD2sXnsFWmtro%3D (Pubitemid 47038187)
4. P Clezardin A Teti 2007 Bone metastasis: pathogenesis and therapeutic implications Clin Exp Metastas 24 599 608 10.1007/s10585-007-9112-8 1:CAS:528:DC%2BD1cXhvFGgtr4%3D (Pubitemid 50003596)
5. HK Datta WF Ng JA Walker, et al. 2008 The cell biology of bone metabolism J Clin Pathol 61 577 587 18441154 10.1136/jcp.2007.048868 1:CAS:528: DC%2BD1cXmvVyks78%3D (Pubitemid 351678208)
6. BF Boyce L Xing 2008 Functions of RANKL/RANK/OPG in bone modeling and remodeling Arch Biochem Biophys 473 139 146 18395508 10.1016/j.abb.2008.03.018 1:CAS:528:DC%2BD1cXlsFOgt7c%3D
7. K Matsuo N Irie 2008 Osteoclast-osteoblast communication Arch Biochem Biophys 473 201 209 18406338 10.1016/j.abb.2008.03.027 1:CAS:528: DC%2BD1cXlsFOgtbs%3D
8. WJ Boyle WS Simonet DL Lacey 2003 Osteoclast differentiation and activation Nature 423 337 342 12748652 10.1038/nature01658 1:CAS:528: DC%2BD3sXjs1ynu7g%3D (Pubitemid 40852708)
9. GC Nicholson M Malakellis FM Collier, et al. 2000 Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL) Clin Sci (Lond) 99 133 140 10.1042/CS19990355 1:CAS:528:DC%2BD3cXmsV2murc%3D (Pubitemid 30614381)
10. YS Hu H Zhou D Myers, et al. 2004 Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclasts J Bone Miner Res 19 89 99 14753741 10.1359/jbmr.0301215 1:CAS:528:DC%2BD2cXnt1KgsQ%3D%3D (Pubitemid 41295142)
11. N Kim Y Kadono M Takami, et al. 2005 Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis J Exp Med 202 589 595 16147974 10.1084/jem.20050978 1:CAS:528:DC%2BD2MXhtVSjs7zM (Pubitemid 41248411)
12. M San-Julian P Diaz-de-Rada E Noain, et al. 2003 Bone metastases from osteosarcoma Int Orthop 27 117 120 12700938 1:STN:280:DC%2BD3s7otFGktg%3D%3D (Pubitemid 36693282)
13. S Avnet A Longhi M Salerno, et al. 2008 Increased osteoclast activity is associated with aggressiveness of osteosarcoma Int J Oncol 33 1231 1238 19020756 1:CAS:528:DC%2BD1cXhsFams7jL
14. T Akiyama CR Dass PF Choong 2008 Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway Mol Cancer Ther 7 3461 3469 19001431 10.1158/1535-7163.MCT-08- 0530 1:CAS:528:DC%2BD1cXhtlGgsrfO
15. T Akiyama PF Choong CR Dass 2010 RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells Clin Exp Metastas 27 207 215 10.1007/s10585-010-9319-y 1:CAS:528:DC%2BC3cXmsFSmtbc%3D
16. T Akiyama CR Dass Y Shinoda, et al. 2010 Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts J Pharm Pharmacol 62 470 476 20604836 1:CAS:528:DC%2BC3cXlsFWnu7k%3D
17. N Miyamoto Y Higuchi K Mori, et al. 2002 Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells Int Immunopharmacol 2 25 38 11789667 10.1016/S1567-5769(01)00134-5 1:CAS:528:DC%2BD38Xjt1ylsQ%3D%3D (Pubitemid 33086801)
18. K Itoh N Udagawa K Matsuzaki M Takami H Amano T Shinki, et al. 2000 Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors J Bone Miner Res 15 1766 1775 10976996 10.1359/jbmr.2000.15.9.1766 1:CAS:528:DC%2BD3cXmsF2mtL0%3D (Pubitemid 30666230)
19. T Kawase K Okuda DM Burns 2005 Immature osteoblastic MG63 cells possess two calcitonin gene-related peptide receptor subtypes that respond differently to [Cys(Acm)(2,7)] calcitonin gene-related peptide and CGRP(8-37) Am J Physiol Cell Physiol 289 C811 C818 15958524 10.1152/ajpcell.00504.2004 1:CAS:528:DC%2BD2MXhtFens7vL (Pubitemid 41361636)
20. HC Blair RF Sidonio RC Friedberg, et al. 2000 Proteinase expression during differentiation of human osteoclasts in vitro J Cell Biochem 78 627 637 10861860 10.1002/1097-4644(20000915)78:4<627::AID-JCB12>3.0.CO;2-3 1:CAS:528:DC%2BD3cXlvFOlu7s%3D (Pubitemid 30620708)
21. S Lossdorfer Z Schwartz L Wang, et al. 2004 Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity J Biomed Mater Res 70 361 369 10.1002/jbm.a.30025 1:STN:280: DC%2BD2czovVCgsA%3D%3D (Pubitemid 39145239)
22. D Granchi E Cenni L Savarino, et al. 2002 Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells Biomaterials 23 2359 2365 12013183 10.1016/S0142-9612(01)00371-4 1:CAS:528:DC%2BD38Xitlaktbg%3D (Pubitemid 34234837)
23. RS Taichman SG Emerson 1996 Human osteosarcoma cell lines MG-63 and SaOS-2 produce G-CSF and GM-CSF: identification and partial characterization of cell-associated isoforms Exp Hematol 24 509 517 8608800 1:CAS:528: DyaK28XislOjs70%3D (Pubitemid 26127501)
24. CD Toma M Svoboda F Arrich, et al. 2007 Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors J Pineal Res 43 206 213 17645699 10.1111/j.1600-079X.2007.00464.x 1:CAS:528:DC%2BD2sXovFantLo%3D (Pubitemid 47077224)
25. J Costa-Rodrigues CA Teixeira P Sampaio, et al. 2010 Characterisation of the osteoclastogenic potential of human osteoblastic and fibroblastic conditioned media J Cell Biochem 109 205 216 19911374 1:CAS:528: DC%2BD1MXhs1Sqt7bO
26. MM Bradford 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 248 254 942051 10.1016/0003-2697(76)90527-3 1:CAS:528: DyaE28XksVehtrY%3D
27. H Hotokezaka E Sakai N Ohara, et al. 2007 Molecular analysis of RANKL-independent cell fusion of osteoclast-like cells induced by TNF-α, lipopolysaccharide, or peptidoglycan J Cell Biochem 101 122 134 17171644 10.1002/jcb.21167 1:CAS:528:DC%2BD2sXkvFeku74%3D (Pubitemid 46652578)
28. M Yamashita F Otsuka T Mukai, et al. 2010 Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling Regul Pept 162 99 108 20346376 10.1016/j.regpep.2010.03.003 1:CAS:528:DC%2BC3cXlvVGisL4%3D
29. H Hotokezaka E Sakai K Kanaoka, et al. 2002 U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells J Biol Chem 277 47366 47372 12237315 10.1074/jbc. M208284200 1:CAS:528:DC%2BD38XptFSrtrw%3D (Pubitemid 36159251)
30. CR Yang JH Wang SL Hsieh, et al. 2004 Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells Cell Death Differ 11 S97 S107 15002040 10.1038/sj.cdd.4401403 1:CAS:528: DC%2BD2cXlsFelurg%3D (Pubitemid 39136802)
31. Q Yang KP McHugh S Patntirapong, et al. 2008 VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin Matrix Biol 27 589 599 18640270 10.1016/j.matbio.2008.06.005
32. HJ Kim Y Lee EJ Chang, et al. 2007 Suppression of osteoclastogenesis by N,N-dimethyl-d-erythro-sphingosine: a sphingosine kinase inhibition-independent action Mol Pharmacol 72 418 428 17504945 10.1124/mol.107.034173 1:CAS:528:DC%2BD2sXosVKrtrc%3D (Pubitemid 47124122)
33. TJ Hall M Schaeublin H Jeker, et al. 1995 The role of reactive oxygen intermediates in osteoclastic bone resorption Biochem Biophys Res Commun 207 280 287 7857277 10.1006/bbrc.1995.1184 1:CAS:528:DyaK2MXjsFKhsbw%3D
34. M Kellinsalmi V Parikka J Risteli, et al. 2007 Inhibition of cyclooxygenase-2 down-regulates osteoclast and osteoblast differentiation and favours adipocyte formation in vitro Eur J Pharmacol 572 102 110 17632097 10.1016/j.ejphar.2007.06.030 1:CAS:528:DC%2BD2sXhtVOlsbrK (Pubitemid 47429646)
35. M Kawashima Y Fujikawa I Itonaga, et al. 2009 The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro Mod Rheumatol 19 192 198 19198759 10.1007/s10165-008-0149-6 1:CAS:528:DC%2BD1MXjvFaqtb8%3D
36. L Hessle KA Johnson HC Anderson, et al. 2002 Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization Proc Natl Acad Sci USA 99 9445 9449 12082181 10.1073/pnas.142063399 1:CAS:528:DC%2BD38XlsVGgt70%3D (Pubitemid 34764633)
37. Y Torii K Hitomi Y Yamagishi, et al. 1996 Demonstration of alkaline phosphatase participation in the mineralization of osteoblasts by antisense RNA approach Cell Biol Int 20 459 464 8931312 10.1006/cbir.1996.0060 1:CAS:528:DyaK28XntVOht7w%3D (Pubitemid 26379884)
38. D Chen M Zhao GR Mundy 2004 Bone morphogenetic proteins Growth Factors 22 233 241 15621726 10.1080/08977190412331279890 1:CAS:528:DC%2BD2MXhtFWrsQ%3D%3D (Pubitemid 40136452)
39. FJ Pixley ER Stanley 2004 CSF-1 regulation of the wandering macrophage: complexity in action Trends Cell Biol 14 628 638 15519852 10.1016/j.tcb.2004.09. 016 1:CAS:528:DC%2BD2cXpt1Wgsrw%3D (Pubitemid 39440612)
40. HJ Knowles NA Athanasou 2008 Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF J Pathol 215 56 66 18283716 10.1002/path.2319 1:CAS:528:DC%2BD1cXmtFKrsr8%3D (Pubitemid 351619876)
41. H Yasuda N Shima N Nakagawa, et al. 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci USA 95 3597 3602 9520411 10.1073/pnas.95.7.3597 1:CAS:528:DyaK1cXitlKjsLY%3D (Pubitemid 28173173)
42. Q Zhao J Shao W Chen, et al. 2007 Osteoclast differentiation and gene regulation Front Biosci 12 2519 2529 17127260 10.2741/2252 1:CAS:528: DC%2BD28Xht1OnsbjF
43. TJ de Vries MG Mullender MA van Duin, et al. 2009 The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts Mol Cancer Res 7 476 488 19372577 10.1158/1541-7786.MCR-08-0219
44. R Battaglino D Kim J Fu, et al. 2002 c-myc is required for osteoclast differentiation J Bone Miner Res 17 763 773 12009006 10.1359/jbmr.2002.17.5.763 1:CAS:528:DC%2BD38XktVSktr4%3D (Pubitemid 34441892)
45. DB Logar R Komadina J Preželj, et al. 2007 Expression of bone resorption genes in osteoarthritis and in osteoporosis J Bone Miner Metab 25 219 225 17593491 10.1007/s00774-007-0753-0 1:CAS:528:DC%2BD2sXmvFalsL8%3D (Pubitemid 47012479)
46. EW Bradley MM Ruan A Vrable, et al. 2008 Pathway crosstalk between Ras/Raf and PI3K in promotion of M-CSF-induced MEK/ERK-mediated osteoclast survival J Cell Biochem 104 1439 1451 18275061 10.1002/jcb.21719 1:CAS:528:DC%2BD1cXosFyktLo%3D (Pubitemid 351961713)
47. GD Roodman 1999 Cell biology of the osteoclast Exp Hematol 27 1229 1241 10428500 10.1016/S0301-472X(99)00061-2 1:STN:280:DyaK1MzlsFCmtg%3D%3D (Pubitemid 29347472)
48. K Strait Y Li DL Dillehay, et al. 2008 Suppression of NF-kappaB activation blocks osteoclastic bone resorption during estrogen deficiency Int J Mol Med 21 521 525 18360699 1:CAS:528:DC%2BD1cXkslKqtrk%3D (Pubitemid 351802648)
49. Y Okada C Pilbeam L Raisz, et al. 2003 Role of cyclooxygenase-2 in bone resorption J UOEH 25 185 195 12813861 1:CAS:528:DC%2BD3sXms1ynsbY%3D (Pubitemid 36759556)
50. KA Blackwell LG Raisz CC Pilbeam 2010 Prostaglandins in bone: bad cop, good cop? Trends Endocrinol Metab 21 294 301 20079660 10.1016/j.tem.2009.12.004 1:CAS:528:DC%2BC3cXlsFaltbk%3D
51. E Cenni D Granchi G Ciapetti, et al. 2001 Interleukin-6 expression by osteoblast-like MG63 cells challenged with four acrylic bone cements J Biomater Sci 12 243 253 10.1163/156856201750180951 1:CAS:528:DC%2BD3MXktFajs7s%3D (Pubitemid 32515009)
52. SM Kakonen GR Mundy 2003 Mechanisms of osteolytic bone metastases in breast carcinoma Cancer 97 834 839 12548583 10.1002/cncr.11132 (Pubitemid 36125820)
53. C Morrissey RL Vessella 2007 The role of tumor microenvironment in prostate cancer bone metastasis J Cell Biochem 101 873 886 17387734 10.1002/jcb.21214 1:CAS:528:DC%2BD2sXnvVSqu7Y%3D (Pubitemid 47040869)
54. H Michael PL Harkonen L Kangas, et al. 2007 Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro Br J Pharmacol 151 384 395 17420779 10.1038/sj.bjp.0707232 1:CAS:528:DC%2BD2sXlslCqtbY%3D (Pubitemid 46842673)